WO1998044929A1 - Composition renfermant une proteine de collagene hydrolysee et de la glucosamine, pour le traitement des arthroses - Google Patents
Composition renfermant une proteine de collagene hydrolysee et de la glucosamine, pour le traitement des arthroses Download PDFInfo
- Publication number
- WO1998044929A1 WO1998044929A1 PCT/US1998/006869 US9806869W WO9844929A1 WO 1998044929 A1 WO1998044929 A1 WO 1998044929A1 US 9806869 W US9806869 W US 9806869W WO 9844929 A1 WO9844929 A1 WO 9844929A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- glucosamine
- collagen protein
- patient
- hydrolyzed collagen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 102000008186 Collagen Human genes 0.000 title claims abstract description 37
- 108010035532 Collagen Proteins 0.000 title claims abstract description 37
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 title claims abstract description 28
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960002442 glucosamine Drugs 0.000 title claims abstract description 28
- 201000008482 osteoarthritis Diseases 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title claims description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000004615 ingredient Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 19
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 3
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000010438 granite Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 23
- 210000002808 connective tissue Anatomy 0.000 abstract description 13
- 238000011069 regeneration method Methods 0.000 abstract description 6
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 229920001436 collagen Polymers 0.000 description 14
- 210000000845 cartilage Anatomy 0.000 description 12
- 206010003246 arthritis Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000005067 joint tissue Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960002849 glucosamine sulfate Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- -1 corticosteroids Chemical class 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
Definitions
- the present invention relates to a composition for treatment of degenerative joint diseases, and to a method of treating arthroses.
- Degenerative joint diseases or arthroses are conditions where degenerative changes in cartilage lead to a breakdown in the integrity of the structural matrix of cartilage or tendonous tissues.
- Conventionally referred to as arthritis the complaints associated with the degenerative changes occur most frequently in individuals over 50.
- Arthritis affects over 40 million 15 Americans (1 in 7). 80% of Americans over 50 have arthritis. Over 45, women experience arthritis 10 times more than men. In short, Arthritis is the primary cause of disability in Americans
- Symptoms include early morning stiffness, 20 stiffness following periods of rest, pain that worsens on joint use and loss of joint function.
- Cartilage provides the cushion and frictionless mobility of. joints.
- cartilage is constantly under a process of natural repair and regeneration. 25 Because of overuse, injury or other causes, many individuals overwhelm their body's ability to keep up with the natural process of repair. The result is cartilage that becomes increasing dry and inflexible leading to pain and eventual joint restriction.
- Steroids such as corticosteroids, and other anti-inflammatory materials, such as non-steroidal anti-inflammatory drugs ("NSAIDs") and high doses of aspirin, are widely used for the treatment of these ailments, Pharmocol. Res. Commun. 10:557-569 (1978) by Vidal et al. While these materials often relieve the pain and swelling associated with maladies arising from connective tissue problems, they offer no support for repair processes.
- NSAIDs non-steroidal anti-inflammatory drugs
- NSAIDs may also inhibit the body's own natural healing processes, leading to further deterioration of the connective tissue.
- These prior efforts may be characterized as providing only temporary palliative or symptomatic relief in as much as they furnish no pharmacological support system for the repair and regeneration of connective tissue.
- An object of the present invention is to provide agents for the treatment of arthroses that are suitable for alleviating and curing effects on arthroses.
- a particular object of the present invention is to provide a novel therapeutic composition comprising nutritional elements in a synergistic combination that is effective in promoting the repair and regeneration of joint and connective tissues.
- a further object of the present invention is to provide a method for treating arthritis by administering to a patient in need of such treatment an effective amount of the present novel therapeutic composition.
- HCP hydrolyzed collagen protein
- glucosamine or a therapeutically acceptable salt
- the present therapeutic composition of HCP and glucosamine has a positive effect on connective tissue maintenance and is capable of offering additional nutritional support for osteoporotic individuals.
- the present invention further contemplates a method of treating arthroses and a method of maintaining joint tissue health.
- the present invention offers the surprising benefit of providing a therapeutic composition which supplies co-factors for the repair and regeneration of connecting tissue, such as cartilage, while concurrently functioning as an analgesic, and a method of treatment using such a composition.
- the present composition includes two essential ingredients: hydrolyzed collagen protein in combination with glucosamine and/or pharmacologically acceptable salts thereof, which, in combination, act synergistically to stimulate both collagen and proteoglycan synthesis.
- Hydrolyzed collagen protein particularly enzymatically hydrolyzed collagen having a molecular weight of up to 80 kilodaltons, capable of being synergistically combined with at least one of glucosamine and pharmacologically acceptable inorganic glucosamine salts herein is available, and is generally described in U.S. Patent No. 4,804,745, the complete disclosure of which is incorporated herein by reference.
- the hydrolyzed collagen protein can have a molecular weight in the range of about 1 to about 300 kilodaltons.
- Lower molecular weight fractions of hydrolysed collagen protein in the range of about 1 to 10 kilodaltons can, if desired, be used alone or in combination with one or more higher molecular weight fractions of hydrolyzed collagen protein.
- Higher molecular weight fractions include hydrolyzed collagen protein and fractions thereof in the range of about 100 to 300 kilodaltons. It has been determined that particularly efficient assimilation characteristics and a particularly good efficiency against arthroses, are observable when hydrolyzed collagens having an average molecular weight of from 10,000 to 80,000 (10 to 80 kilodaltons) are employed. Higher molecular weight preparations are generally less readily soluble in cold water. Lower molecular weight products are also more difficult to prepare in acceptable forms for application.
- glucosamine and pharmaceutically acceptable salts thereof are available, and, in general, are described in U.S. Patent No. 5,587,363 and U.S. Patent No. 5,364,845, the complete disclosures of which are incorporated herein by reference.
- Suitable salts include, among others, glucosamine sulfate and glucosamine hydrochloride.
- Glucosamine may, if desired, include or be comprised of crude forms thereof.
- Glucosamine and its pharmaceutically acceptable salts combine well with the hydrolyzed collagen protein base of the composition, providing the primary substrates for both collagen and proteoglycan synthesis.
- Glucosamine is the preferred substrate for proteoglycan synthesis, including chondroitin sulfates and hyaluronic acid.
- the glucosamine is, preferably, in a salt form so as to facilitate its delivery and uptake by the patient.
- the preferred salt forms are glucosamine sulfate and glucosamine hydrochloride.
- patient includes veterinary patients, such as veterinary mammalian patients, and also human patients unless otherwise stated.
- Glucosamine has been shown to be rapidly and almost completely absorbed into humans and animals after oral administration. A significant portion of the ingested glu ⁇ samine localizes to cartilage and joint tissues, where it remains for long time periods. This indicates that oral adrninistration of glucosamine reaches connective tissues, where glucosamine is incorporated into newly-synthesized connective tissue.
- glucosamine can lead to increased synthesis of collagen and glycosaminoglycans from fibroblasts which is the first step in repair of connective tissues.
- Glucosamine and its pharmaceutically acceptable salts have also exhibited reproducible improvement in symptoms and cartilage integrity in humans with osteoarthritis in a series of studies, such Tapadinhas
- the present therapeutic composition manifests a number of unique and unexpected advantages.
- Clinical research in arthroses indicates that the synergistic effects of the therapeutic composition exceed the benefits obtainable from adrrjinistration of the ingredients singly. This unexpected result obtains from effects seen at the level of connective tissue.
- This increase in synthesis is exceptional in that the enzymatic mechanisms related to collagen and glycosaminglycan synthesis are enhanced well beyond normal activity levels.
- chondrocyte inhibitory factors such as cytokines, interferons and prostoglandins may be responsible for this unexpectedly enhanced activity, or that the components themselves may have a catalytic or co-catalytic effect. Additional findings relate to a localized reduction in inflammatory products from activated mononuclear cells known to decrease fibroblast proliferation.
- the present therapeutic composition in principle has the effect of maintaining and re-establishing overall composition of cartilage glycosaminoglycans, in spite of tissue age.
- the data suggest that the proportion of chondroitin sulfate, which generally falls with increasing age, is maintained versus that of keratin sulfate and hyaluronate. Therefore, in vivio, the consistent supplementation with the present therapeutic composition may forestall at least some age-related changes in cartilage composition heretofore considered to affect the ability of proteoglycan elements to aggregate with one another or to interact with collagen.
- Glucosamine sulfate and its pharmaceutically acceptable salts taken supplementary can be used by the patient to produce primarily glycosamineglycans ("GAGs"), and secondarily collagen.
- GAGs glycosamineglycans
- the present therapeutic composition advantageously enables a relative enhancement in GAG synthesis with a concomitant reduction in consumption of glucosamine and its salts in collagen synthesis.
- the present invention offers further advantages over conventional compositions and methods of treatment. Among these, administration of the present therapeutic composition advantageously does not require ever increasing dosages of the essential ingredients during the treatment period. This advantage results because the present therapeutic composition provides an effective balanced combination of analgesia and pharmacological support for the treatment of the underlying disease. Maintenance dosing at a reduced dosage level can, where appropriate, be administered thereafter.
- the present therapeutic composition can be administered to the patient in a number of efficacious forms.
- the present composition can be supplied in a powder form which is at least substantially homogeneous compositionally and has a substantially homogeneous particle size distribution.
- the substantially homogeneous particle size distribution means that as a result of mixing, blending or otherwise effectively combining the at least two essential ingredients, the hydrolyzed collagen protein plus the glucosamine and/or its acceptable salts each have the desired pre-selected particle sizes.
- the two ingredients can be combined and the combined form can be rendered pulverulent such that the particles themselves are substantially homogeneous from the compositional standpoint.
- fluidized bed techniques can be adapted for the preparation of the foregoing powder formulations.
- the scoop form of the composition can be measured out dry, such as with a measuring scoop, for administration to the patient.
- a measuring scoop for administration to the patient.
- the dosage is scooped in dry form and can be added to the veterinary patient's diet, such as in the animal feed.
- the scoop method can also be similarly used.
- the present invention can also be administered to the patient, human or veterinary mammalian patient, in capsule or tablet form. Tablets can, if desired, be coated or uncoated. Suitable tableting procedures include those generally described in Perry's Chemical Engineer's Handbook, page 8-62 to 8- 64 (4 th Edition 1963), Ullmann's Encyclopedia of Industrial Chemistry, volume A19, pages 245-256 (Springer Verlag 1991), Ullmann's Encyclopedia of Industrial Chemistry, volume B2,pages 7-31 to 7-37 (Springer Verlag
- the present therapeutic composition can also be administered in capsule or gel-cap form.
- the size of each dosage and the interval of dosing to the patient effectively determines the size and shape of the tablet or capsule.
- each capsule and each tablet contains both of the present essential ingredients in pre-determined amounts to simplify the patient's treatment regimen.
- the present therapeutic composition can be administered orally. Oral administration is preferred because of convenience to the patient as well as the dosing schedule.
- the composition can be administered in powder form, but is, for at least some patients, more readily administered in solution.
- the solution media can be water or any consumable liquid or beverage.
- the beverage and consumable liquids are non-carbonated, and can, if desired, also be non-alcoholic.
- the therapeutic composition can be provided for administration in the form of a so- called instantized (powdered) formulation for ready swallowing or ready dissolution in the selected liquid for subsequent administration to the patient, or can be provided in pre-mixed solution for immediate use or as a pre-mixed dilutable concentrate.
- the pre-mixed form can be packaged in suitable containers such as, cans, bottles or the like for storage prior to use.
- a predetermined amount of a powdered solid pre-mix formulation can also be packaged in one or more sachets.
- the composition can also be administered in the form of a paste, compact, emulsion, elixir, granules, syrup, lozenges, gum, or candied formulation.
- the two essential ingredients are relatively neutral in taste, and thus they can, if desired, be combined with flavoring materials, sweeteners, and/or aroma ingredients.
- the composition can also include other additives known in the nutritional and pharmaceutical arts such as, for instance, multi-vitamins, minerals, or nutritional elements, among others.
- the composition includes relative amounts of the two essential ingredients.
- compositions are formulated to provide an effective amount of hydrolyzed collagen protein, such as in adrninistration, e.g. dosing, to the patient.
- the hydrolyzed collagen is, in general, dosed so that the patient, human or veterinary mammalian patient, can receive a hydrolyzed collagen dosage in the range of 0.5 to 12 grams.
- An efficient therapy can involve daily doses of from 5 to 12 grams hydrolyzed collagen protein.
- the present compositions are formulated to provide an effective amount of the glucosamine and/or its pharmaceutically acceptable salts, such as in the administration, e.g. dosing, to the patient.
- the dosage is in a range of about 0.25 to 3.0 grams, depending on the patient, human or veterinary, receiving treatment.
- the patent can receive about 0.75 gram to about 2.0 grams of the glucosamine and/or its pharmaceutically acceptable salts.
- the present therapeutic composition is administered to a patient, such as a human patient, in which the daily dosage is about 7 to about 8 grams of hydrolyzed collagen protein in combination with about 1.5 to about 2.0 grams of the glucosamine and/or its pharmaceutically acceptable salts, e.g. in a weight ratio of about 3.5 to about 5.3.
- the relative amounts of effective ingredients within a dose or dosing schedule can be adjusted as appropriate for efficacious administration to veterinary patients.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98915336A EP0991413A1 (fr) | 1997-04-10 | 1998-04-09 | Composition renfermant une proteine de collagene hydrolysee et de la glucosamine, pour le traitement des arthroses |
AU69545/98A AU6954598A (en) | 1997-04-10 | 1998-04-09 | Composition comprising a hydrolysed collagen protein and glucosamine for the treatment of arthroses |
JP54303598A JP2001524080A (ja) | 1997-04-10 | 1998-04-09 | 関節炎の治療用加水分解コラーゲンタンパク質およびグルコサミンを含む組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4322697P | 1997-04-10 | 1997-04-10 | |
US60/043,226 | 1997-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998044929A1 true WO1998044929A1 (fr) | 1998-10-15 |
Family
ID=21926140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/006869 WO1998044929A1 (fr) | 1997-04-10 | 1998-04-09 | Composition renfermant une proteine de collagene hydrolysee et de la glucosamine, pour le traitement des arthroses |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0991413A1 (fr) |
JP (1) | JP2001524080A (fr) |
AU (1) | AU6954598A (fr) |
WO (1) | WO1998044929A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001072582A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 機能性経口組成物 |
US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
WO2001093832A3 (fr) * | 2000-06-02 | 2002-04-25 | Procter & Gamble | Compositions aqueuses de protection des cartilages présentant des contraintes posologiques déterminées pour une administration efficace |
WO2001093833A3 (fr) * | 2000-06-02 | 2002-04-25 | Procter & Gamble | Necessaires et methodes pour optimiser l'efficacite de compositions de protection des cartilages |
WO2002098449A1 (fr) * | 2001-06-01 | 2002-12-12 | Nippon Meat Packers, Inc. | Medications pour lesions des articulations et aliments fonctionnels |
JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
JP2004507490A (ja) * | 2000-08-29 | 2004-03-11 | アナスタシアデス,タソース,ピー | 関節炎の処置及びそれ用の組成物 |
WO2008009798A1 (fr) * | 2006-07-19 | 2008-01-24 | Bio Serae Laboratoires Sa | Composition a base de d-glucosamine, de lactoferrine et de chondroitine sulfate pour prevenir et/ou pour traiter les maladies articulaires dégénératives |
WO2018166807A1 (fr) * | 2017-03-15 | 2018-09-20 | Rousselot B.V. | Compositions de peptides de collagène hydrolysé et de micro-organismes commensaux et leurs procédés |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4804745A (en) * | 1986-07-25 | 1989-02-14 | Deutsche Gelatine-Fabriken Stoess & Co. Gmbh | Agents for the treatment of arthroses |
WO1994022453A1 (fr) * | 1993-03-31 | 1994-10-13 | Nutramax Laboratories, Inc. | Composition a base de sucres amines et de glycosaminoglycannes pour le traitement et la reparation du tissu conjonctif |
-
1998
- 1998-04-09 WO PCT/US1998/006869 patent/WO1998044929A1/fr not_active Application Discontinuation
- 1998-04-09 AU AU69545/98A patent/AU6954598A/en not_active Abandoned
- 1998-04-09 EP EP98915336A patent/EP0991413A1/fr not_active Withdrawn
- 1998-04-09 JP JP54303598A patent/JP2001524080A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4804745A (en) * | 1986-07-25 | 1989-02-14 | Deutsche Gelatine-Fabriken Stoess & Co. Gmbh | Agents for the treatment of arthroses |
WO1994022453A1 (fr) * | 1993-03-31 | 1994-10-13 | Nutramax Laboratories, Inc. | Composition a base de sucres amines et de glycosaminoglycannes pour le traitement et la reparation du tissu conjonctif |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
JP2001072582A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 機能性経口組成物 |
WO2001093832A3 (fr) * | 2000-06-02 | 2002-04-25 | Procter & Gamble | Compositions aqueuses de protection des cartilages présentant des contraintes posologiques déterminées pour une administration efficace |
WO2001093833A3 (fr) * | 2000-06-02 | 2002-04-25 | Procter & Gamble | Necessaires et methodes pour optimiser l'efficacite de compositions de protection des cartilages |
JP2004507490A (ja) * | 2000-08-29 | 2004-03-11 | アナスタシアデス,タソース,ピー | 関節炎の処置及びそれ用の組成物 |
WO2002098449A1 (fr) * | 2001-06-01 | 2002-12-12 | Nippon Meat Packers, Inc. | Medications pour lesions des articulations et aliments fonctionnels |
JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
WO2008009798A1 (fr) * | 2006-07-19 | 2008-01-24 | Bio Serae Laboratoires Sa | Composition a base de d-glucosamine, de lactoferrine et de chondroitine sulfate pour prevenir et/ou pour traiter les maladies articulaires dégénératives |
FR2903906A1 (fr) * | 2006-07-19 | 2008-01-25 | Bio Serae Lab | Composition pour prevenir et/ou traiter les maladies articulaires degeneratives. |
WO2018166807A1 (fr) * | 2017-03-15 | 2018-09-20 | Rousselot B.V. | Compositions de peptides de collagène hydrolysé et de micro-organismes commensaux et leurs procédés |
US11110147B2 (en) | 2017-03-15 | 2021-09-07 | Rousselot B.V | Collagen hydrolysates as a beneficial prebiotic and their effect on joint inflammation and osteoarthritis |
Also Published As
Publication number | Publication date |
---|---|
JP2001524080A (ja) | 2001-11-27 |
EP0991413A1 (fr) | 2000-04-12 |
AU6954598A (en) | 1998-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0178602B1 (fr) | Traitement des maladies inflammatoires dégénératives des tissus | |
Brandt | Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo | |
Moskowitz | Role of collagen hydrolysate in bone and joint disease | |
US4772591A (en) | Method for accelerated wound healing | |
JP2971579B2 (ja) | 結合組織の治療と回復のためのアミノ糖とグリコサミノグリカン組成物 | |
US6492349B1 (en) | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue | |
JP5662492B2 (ja) | 抗炎症製剤 | |
JPS6339821A (ja) | 関節の治療薬 | |
EP1276485B1 (fr) | Compositions utiles pour le traitement de pathologies des tissus conjonctifs | |
US6911215B2 (en) | Treating arthritis in animals with dietary supplements | |
CA2652537A1 (fr) | Compositions pharmaceutiques veterinaires de traitement de douleur et d'inflammation | |
EP0991413A1 (fr) | Composition renfermant une proteine de collagene hydrolysee et de la glucosamine, pour le traitement des arthroses | |
AU2009304002B2 (en) | A medicinal product and treatment | |
CA2240165A1 (fr) | Regime alimentaire a base de complements nutritionnels permettant de soulager les symptomes de l'arthrite | |
AU767689B2 (en) | Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration | |
ES2325392B1 (es) | Composicion para el tratamiento de la artrosis. | |
JP2003155250A (ja) | 関節痛を緩和する目的の健康食品 | |
JP2007522232A (ja) | 軟骨に影響する状態において使用するための組成物及び方法 | |
KR100420560B1 (ko) | 포도당과 아미노산의 상승작용에 의한 관절염 및관절손상의 예방 및 치료제 | |
US6218433B1 (en) | Use of pharmaceutical composition in the treatment of traumatic arthritis in horses | |
EP4412637A1 (fr) | Méthode de traitement d'articulations squelettiques, composition et utilisations associées | |
Singh et al. | A Review on Etiopathogenesis and Medicinal Management of Ante Brachial Deformities in Growing Dogs | |
EP2243478A1 (fr) | Composition pharmaceutique comprenant la combinaison d'un agent anti-arthritique et d'un agent inhibiteur de l'interleukine 1, utile pour le contrôle et le traitement de l'ostéoarthrose et de maladies associées | |
WO2004000364A1 (fr) | Preparation a base de polydimethylsiloxane pour le traitement de problemes lies aux clous, cartilages, os, articulations, muscles et tendons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 543035 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09414825 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998915336 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998915336 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998915336 Country of ref document: EP |